Infinity Bio, Inc. is a biotechnology company that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform.
The company’s core technology comprehensively measures antibody reactivities against all known human viruses, human proteins (autoimmunity), and allergen proteins.
Infinity Bio’s MIPSA technology was developed at Johns Hopkins University in Dr. H. Benjamin Larman’s Laboratory of Precision Immunology. It builds off of decades of work in the fields of genomics, proteomics, immunology, and bioinformatics to enable best-in-class data quality and cost efficiency.
